Breast Cancer Brain Metastasis: A Comprehensive Review

Overview

Journal JCO Oncol Pract

Specialty Oncology

Date 2024 May 15

PMID 38748968

Authors

Akshara S Raghavendra

Nuhad K Ibrahim

Affiliations

Soon will be listed here.

Abstract

The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies depending on the number, location, and size of brain metastases. Common symptoms include headache, neurologic deficits, and seizures. Diagnosis of BCBM typically relies on neuroimaging techniques, such as magnetic resonance imaging and computed tomography scans. Local therapies, such as surgery and stereotactic radiosurgery, can be used to control tumor growth and relieve symptoms. Whole-brain radiotherapy has been a mainstay of treatment for BCBM, but its use has been associated with cognitive decline. Systemic therapy with chemotherapy and targeted agents plays an increasingly important role in the management of BCBM. Novel agents, such as human epidermal growth factor receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors, have shown promising results in improving survival for patients with HER2-positive and triple-negative BCBM. This comprehensive review synthesizes current knowledge, clinical insights, and evolving paradigms to provide a robust understanding and roadmap for optimizing the diagnosis and management of BCBM.

Citing Articles

Editorial: Advances of brain metastasis in breast cancer.

Lv W, Brufsky A, Ochiya T Front Hum Neurosci. 2025; 19:1554890.

PMID: 39916730 PMC: 11794519. DOI: 10.3389/fnhum.2025.1554890.

Regulation of metastatic organotropism.

Dunbar K, Efe G, Cunningham K, Esquea E, Navaridas R, Rustgi A Trends Cancer. 2024; 11(3):216-231.

PMID: 39732596 PMC: 11903188. DOI: 10.1016/j.trecan.2024.11.012.

Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.

Fabian A, Buergy D, Weykamp F, Horner-Rieber J, Bernhardt D, Boda-Heggemann J Clin Exp Metastasis. 2024; 42(1):6.

PMID: 39708074 PMC: 11663153. DOI: 10.1007/s10585-024-10326-x.

Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis.

Almeida N, Kuo C, Schrand T, Rupp J, Madhugiri V, Goulenko V Cancers (Basel). 2024; 16(20).

PMID: 39456645 PMC: 11506708. DOI: 10.3390/cancers16203551.

References

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

Znidaric T, Gugic J, Marinko T, Gojkovic Horvat A, Paulin Kosir M, Golo D . Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes. Breast J. 2019; 25(6):1117-1125. DOI: 10.1111/tbj.13433. View

Leone J, Leone B . Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015; 4:33. PMC: 4657380. DOI: 10.1186/s40164-015-0028-8. View

Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F . Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2012; 14(1):64-71. DOI: 10.1016/S1470-2045(12)70432-1. View

Xiong Y, Cao H, Zhang Y, Pan Z, Dong S, Wang G . Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study. World Neurosurg. 2019; 128:e823-e834. DOI: 10.1016/j.wneu.2019.04.262. View

Giglio P, Gilbert M . Cerebral radiation necrosis. Neurologist. 2003; 9(4):180-8. DOI: 10.1097/01.nrl.0000080951.78533.c4. View

Sun M, Yun Y, Liu H, Yu Z, Yang F, Xu L . Brain metastasis in de novo breast cancer: An updated population-level study from SEER database. Asian J Surg. 2022; 45(11):2259-2267. DOI: 10.1016/j.asjsur.2021.12.037. View

Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T . Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(7):880-888. DOI: 10.1016/S1470-2045(18)30256-0. View

Glantz M, Lafollette S, Jaeckle K, Shapiro W, Swinnen L, Rozental J . Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17(10):3110-6. DOI: 10.1200/JCO.1999.17.10.3110. View

10.

Borges V, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I . Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018; 4(9):1214-1220. PMC: 6143009. DOI: 10.1001/jamaoncol.2018.1812. View

11.

Vogelbaum M, Brown P, Messersmith H, Brastianos P, Burri S, Cahill D . Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021; 40(5):492-516. DOI: 10.1200/JCO.21.02314. View

12.

Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C . ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020; 26(12):2789-2799. DOI: 10.1158/1078-0432.CCR-19-3258. View

13.

Niwinska A, Murawska M, Pogoda K . Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2009; 21(5):942-8. DOI: 10.1093/annonc/mdp407. View

14.

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

15.

Narita Y, Shibui S . Strategy of surgery and radiation therapy for brain metastases. Int J Clin Oncol. 2009; 14(4):275-80. DOI: 10.1007/s10147-009-0917-0. View

16.

Duman J, Dinh J, Zhou W, Cham H, Mavratsas V, Paveskovic M . Memantine prevents acute radiation-induced toxicities at hippocampal excitatory synapses. Neuro Oncol. 2017; 20(5):655-665. PMC: 5892158. DOI: 10.1093/neuonc/nox203. View

17.

Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L . Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002; 128(4):214-8. DOI: 10.1007/s00432-002-0323-8. View

18.

Hardesty D, Nakaji P . The Current and Future Treatment of Brain Metastases. Front Surg. 2016; 3:30. PMC: 4879329. DOI: 10.3389/fsurg.2016.00030. View

19.

Soffietti R, Ducati A, Ruda R . Brain metastases. Handb Clin Neurol. 2012; 105:747-55. DOI: 10.1016/B978-0-444-53502-3.00021-5. View

20.

Saleem A, Searle G, Kenny L, Huiban M, Kozlowski K, Waldman A . Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res. 2015; 5:30. PMC: 4424224. DOI: 10.1186/s13550-015-0103-5. View